Polaris Group
This article was originally published in Start Up
Executive Summary
Polaris Group's Phase II candidate is a microbial enzyme that degrades arginine, an amino acid crucial to tumor cell metabolism and growth. Depleting arginine from the blood can control tumor growth, but normal cells retain their ability to synthesize arginine so should not be harmed by the enzyme's effects.